GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » Cash Flow from Investing

Processa Pharmaceuticals (Processa Pharmaceuticals) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Processa Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Processa Pharmaceuticals gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Processa Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Processa Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals Cash Flow from Investing Chart

Processa Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Processa Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Processa Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Processa Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Processa Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Processa Pharmaceuticals  (NAS:PCSA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Processa Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Processa Pharmaceuticals's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Processa Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Processa Pharmaceuticals's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Processa Pharmaceuticals's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Processa Pharmaceuticals's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Processa Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Processa Pharmaceuticals's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Processa Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Processa Pharmaceuticals's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Processa Pharmaceuticals paid $0.00 Mil for other investing activities.


Processa Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals (Processa Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
Executives
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076

Processa Pharmaceuticals (Processa Pharmaceuticals) Headlines

From GuruFocus

PCS12852 Improves Gastric Emptying in Gastroparesis Patients

By Value_Insider Value_Insider 11-08-2022